InventisBio and Betta Pharma to co-develop novel NSCLC drug

InventisBio (Shanghai) has signed a collaboration agreement with fellow China-based Betta Pharma.

Under this agreement, InventisBio will out-license D-0316's right in China (including mainland China, Hong Kong and Taiwan) to Betta Pharma and to co-develop this drug in China. Betta Pharma will have the exclusive commercialization rights of D-0316 product in China.

D-0316 is a third-generation EGFR-T790M tyrosine kinase inhibitor discovered and developed independently by InventisBio. It is mainly used for the treatment of EGFR-mutant non-small cell lung cancer. The drug is currently in a Phase I clinical trial in China. Betta Pharma will pay upfront and R&D milestones to InventisBio totaling 230 million renminbi ($33 million). After the product is marketed commercially, Betta Pharma will pay various sales milestones and tiered royalties based on annual sales.